Evidence map›Paper›PMID 41961901›Full record

ReviewArchiv der Pharmazie2026

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV.

Debora I Leite, Fernando B Macedo, Murilo Marinho de C Lima, Isabelle S Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S Costa, Stella C Duarte, Sarah Moon, Stefany de Castro B Moura, Andressa P de Oliveira and 2 more

Abstract readReview
In one paragraph

Review in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Debora I LeiteFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.
Fernando B MacedoFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.
Murilo Marinho de C LimaInstituto Federal do Rio de Janeiro - IFRJ, Rua Professor Carlos Wenceslau, Rio de Janeiro, Rio de Janeiro, Brazil.
Isabelle S BrumFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.
Jonathan Fragoso Miranda de OliveiraFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.
Ana Clara S CostaFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.
Stella C DuarteFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.
Sarah MoonFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.
Stefany de Castro B MouraFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.
Andressa P de OliveiraFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.
Nubia BoechatFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0003-0146-2218
Monica M BastosFundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos, Farmanguinhos - Fiocruz, Laboratório de Síntese de Fármacos - LASFAR, Rio de Janeiro, Rio de Janeiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dihydropyrimidinones (DHPMs), also referred to as pyrimidinones, are privileged structures widely employed in the search for new compounds capable of inhibiting HIV replication. This core is found in natural alkaloids isolated from marine sponge species, which are known to inhibit the binding of the viral surface protein gp120 to the CD4 receptor of target cells. In addition, DHPMs exhibit a close structural relationship with nucleic acids, macromolecules that constitute the genetic material of both living organisms and viruses. Furthermore, the DHPM nucleus is present in several important anti-HIV drugs that inhibit reverse transcriptase and integrase enzymes, indicating that the use of these privileged structures represents a faster and more promising approach for the development of novel HIV inhibitors. In this review, we provide an overview of DHPM-based compounds as potential future trends in AIDS treatment, with a focus on studies published over the last 10 years. Overall, our analysis indicates that compounds containing the DHPM core generally display high potency against multiple HIV targets and may overcome antiviral resistance, reinforcing the relevance of this pharmacophoric fragment for the development of effective and innovative antiretroviral therapies.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsPyrimidinonesAnimalsChemistry, PharmaceuticalHumansMolecular StructureReverse Transcriptase InhibitorsStructure-Activity RelationshipVirus ReplicationAnti-HIV AgentsPyrimidinonesReverse Transcriptase InhibitorsAIDSHIVintegrasepyrimidinonesreverse transcriptase

Identifiers

PMID41961901
PMCPMC13068300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.